Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1,500 million. Of these notes, $400 million will mature in 2018 and will bear interest at an annual rate of 2.300%; $700 million will mature in 2023 and will bear interest at an annual rate of 4.000% and $400 million will mature in 2043 and will bear interest at an annual rate of 5.250%. The 2.300% notes due 2018, the 4.000% notes due 2023 and the 5.250% notes due in 2043 were priced to yield 2.344%, 4.067% and 5.307%, respectively. Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene’s clinical and pre-clinical programs, capital expenditures, general corporate development activities, meeting working capital needs, share repurchases of Celgene’s common stock and repayment of some or all of Celgene’s outstanding commercial paper. The offering is expected to close on August 6, 2013. Barclays, Citigroup, Deutsche Bank Securities and J.P. Morgan are acting as joint book-running managers, and HSBC Securities is acting as a co-manager. A copy of the prospectus supplement and the accompanying base prospectus, which is filed as part of Celgene’s effective shelf registration statement on Form S-3 (File No. 333-169731), may be obtained from any of the joint book-running managers by calling Barclays at 1-888-603-5847, Citigroup at 1-800-831-9146, Deutsche Bank Securities at 1-800-503-4611 and J.P. Morgan collect at 1-212-834-4533, or from the co-manager by calling HSBC Securities at 1-866-811-8049. An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at www.sec.gov. The notes are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-169731) that Celgene previously filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the notes described herein, nor shall there be any sale of these notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction. The offering of the notes will be made only by means of a prospectus supplement and the accompanying base prospectus.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.